Skip to Main Content

Author Details

Chi-Ping Day
Center for Cancer Research, National Cancer Institute
2002
49
23
Prashant Mali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37301330Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response.Pharmacol Ther2023
37721939Exploring tumor-normal cross-talk with TranNet: Role of the environment in tumor progression.PLoS Comput Biol2023
37333132Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms.bioRxiv2023
36945455Exploring tumor-normal cross-talk with TranNet: role of the environment in tumor progression.bioRxiv2023
37301330Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response.Pharmacol Ther2023
37173324Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.Nat Commun2023
37721939Exploring tumor-normal cross-talk with TranNet: Role of the environment in tumor progression.PLoS Comput Biol2023
36945455Exploring tumor-normal cross-talk with TranNet: role of the environment in tumor progression.bioRxiv2023
37173324Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.Nat Commun2023
37333132Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms.bioRxiv2023
35180384Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies.Cancer Cell2022
35953723Publisher Correction: A T cell resilience model associated with response to immunotherapy in multiple tumor types.Nat Med2022
35501486A T cell resilience model associated with response to immunotherapy in multiple tumor types.Nat Med2022
36347238The Hitchhiker's Guide across a Waddington's landscape of melanoma.Dev Cell2022
35921407Cross-species identification of cancer resistance-associated genes that may mediate human cancer risk.Sci Adv2022
35718707Making a mouse out of a molehill: how precision modeling repurposes drugs for congenital giant nevi.Trends Cancer2022
36509773Broad misappropriation of developmental splicing profile by cancer in multiple organs.Nat Commun2022
36497367Sex Biases in Cancer and Autoimmune Disease Incidence Are Strongly Positively Correlated with Mitochondrial Gene Expression across Human Tissues.Cancers (Basel)2022
35317524A novel PD-L1-targeted shark V<sub>NAR</sub> single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer.Mol Ther Oncolytics2022
35180384Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies.Cancer Cell2022
35501486A T cell resilience model associated with response to immunotherapy in multiple tumor types.Nat Med2022
35718707Making a mouse out of a molehill: how precision modeling repurposes drugs for congenital giant nevi.Trends Cancer2022
36509773Broad misappropriation of developmental splicing profile by cancer in multiple organs.Nat Commun2022
36497367Sex Biases in Cancer and Autoimmune Disease Incidence Are Strongly Positively Correlated with Mitochondrial Gene Expression across Human Tissues.Cancers (Basel)2022
35953723Publisher Correction: A T cell resilience model associated with response to immunotherapy in multiple tumor types.Nat Med2022
35921407Cross-species identification of cancer resistance-associated genes that may mediate human cancer risk.Sci Adv2022
36347238The Hitchhiker's Guide across a Waddington's landscape of melanoma.Dev Cell2022
35317524A novel PD-L1-targeted shark V<sub>NAR</sub> single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer.Mol Ther Oncolytics2022
34389658Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.Clin Cancer Res2021
33888600Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.Mol Cancer Res2021
33568347Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.Clin Cancer Res2021
34389658Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.Clin Cancer Res2021
34433909Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.Oncogene2021
34941392Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.Science2021
34642183Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages.Cancer Res2021
34635800Correction: Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.Oncogene2021
33568347Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.Clin Cancer Res2021
33888600Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.Mol Cancer Res2021
34941392Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.Science2021
34433909Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.Oncogene2021
34642183Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages.Cancer Res2021
34635800Correction: Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.Oncogene2021
32284588Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.Nat Med2020
31949145Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis.Nat Commun2020
32103175Epigenetic therapy inhibits metastases by disrupting premetastatic niches.Nature2020
32284588Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.Nat Med2020
32807809Strength of immune selection in tumors varies with sex and age.Nat Commun2020
32657358PhISCS-BnB: a fast branch and bound algorithm for the perfect tumor phylogeny reconstruction problem.Bioinformatics2020
31949145Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis.Nat Commun2020
32103175Epigenetic therapy inhibits metastases by disrupting premetastatic niches.Nature2020
  • 1 - 50 of 98

Recommended Authors

Shruthy Suresh
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 0
Minhyung Kim
Roswell Park Comprehensive Cancer Center
Career Start Year 2010
Number of shared co-authors 0
Mitchell P Levesque
University Hospital Zurich
Career Start Year 2009
Number of shared co-authors 12
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 9
Phil F Cheng
University Hospital of Zurich
Career Start Year 2007
Number of shared co-authors 10
Daniel Schramek
University of Toronto
Career Start Year 2005
Number of shared co-authors 0
Stacey J Adam
Foundation for the National Institutes of Health
Career Start Year 2004
Number of shared co-authors 2
Ivy X Chen
Massachusetts General Hospital
Career Start Year 2002
Number of shared co-authors 0
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2002
Number of shared co-authors 0
Monte M Winslow
Stanford University School of Medicine
Career Start Year 2002
Number of shared co-authors 2
Susan L Woods
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 2
Daniel Zingg
Netherlands Cancer Institute
Career Start Year 2001
Number of shared co-authors 5
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Career Start Year 1999
Number of shared co-authors 0
Alana L Welm
Huntsman Cancer Institute, University of Utah
Career Start Year 1999
Number of shared co-authors 3
Lianbo Yu
The Ohio State University
Career Start Year 1997
Number of shared co-authors 0
Marc Vooijs
Maastricht University Medical Centre+
Career Start Year 1997
Number of shared co-authors 0
Hae-Ock Lee
College of Medicine, The Catholic University of Korea
Career Start Year 1996
Number of shared co-authors 0
Christopher Ryan Miller
University of Illinois at Urbana-Champaign
Career Start Year 1996
Number of shared co-authors 6
Alexander D Borowsky
University of California Davis Health
Career Start Year 1995
Number of shared co-authors 3
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 1
Jan Paul Medema
Oncode Institute
Career Start Year 1993
Number of shared co-authors 3
Marcus Bosenberg
Yale School of Medicine
Career Start Year 1992
Number of shared co-authors 17
Ashani T Weeraratna
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Career Start Year 1992
Number of shared co-authors 16
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Lionel Larue
Institut Curie, PSL Research University, INSERM U1021
Career Start Year 1987
Number of shared co-authors 11
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 7
Grant A McArthur
University of Melbourne
Career Start Year 1986
Number of shared co-authors 8
David E Fisher
Cutaneous Biology Research Center, Mass. General Hospital, Harvard Medical School
Career Start Year 1983
Number of shared co-authors 15
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 10
Norman E Sharpless
National Cancer Institute
Career Start Year 1945
Number of shared co-authors 1

Collaborators

Glenn Merlino
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 34
Eva P??rez-Guijarro
National Cancer Institute, National Institutes of Health (NIH)
Co-authored papers 10
Kerrie L Marie
The University of Manchester
Co-authored papers 6
Mien-Chie Hung
Co-authored papers 6
Helen T Michael
National Cancer Institute, National Institutes of Health
Co-authored papers 5
Maxwell P Lee
National Cancer Institute, National Institutes of Health
Co-authored papers 4
M Raza Zaidi
Northwell Health Cancer Institute
Co-authored papers 4
Kenneth Aldape
National Cancer Institute
Co-authored papers 4
Andrew E Aplin
Thomas Jefferson University
Co-authored papers 3
Howard H Yang
Center for Cancer Research, National Cancer Institute
Co-authored papers 3
Eytan Ruppin
National Cancer Institute
Co-authored papers 3
Jorge Silvio Gutkind
Moores Cancer Center, University of California San Diego
Co-authored papers 3
Yardena Samuels
Weizmann Institute of Science
Co-authored papers 3
Hannah Carter
University of California San Diego
Co-authored papers 2
Silvia Coma
Boston Children's Hospital and Dana-Farber Cancer Institute
Co-authored papers 2
Giorgio Trinchieri
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Jonathan A Pachter
Laufer Center for Physical and Quantitative Biology, Stony Brook University
Co-authored papers 2
Kyle Ford
University of California San Diego
Co-authored papers 2
Radomir M Slominski
University of Alabama at Birmingham
Co-authored papers 2
Prashant Mali (CM4AI)
University of California San Diego
Co-authored papers 2
Anup Mahurkar
Co-authored papers 2
John D Carpten
Co-authored papers 2
Justine S Paradis
Moores Cancer Center, University of California San Diego
Co-authored papers 2
Nadia Arang
Moores Cancer Center, University of California San Diego
Co-authored papers 2
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Xingyu Wu
Moores Cancer Center, University of California San Diego
Co-authored papers 2
Heinz Arnheiter
National Institute of Neurological Disorders and Stroke, National Institute of Health
Co-authored papers 2
Nicholas P Restifo
National Cancer Institute, National Institutes of Health (NIH)
Co-authored papers 2
Ludmil B Alexandrov
Moores Cancer Center, university of california san diego
Co-authored papers 2
Cari Graff-Cherry
Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research
Co-authored papers 2
Release 1.2